



Application Number: 09/083,150

22852

CPA Filed: March 29, 2001

PATENT TRADEMARK OFFICE

First Named Inventor: Boudiaf BOUSSOUIRA et al.

Group Art Unit: 1617

Examiner: E. Webman

Attorney Docket Number: 5725.0306-00

Attorney Customer Number: 22,852

RCE 11600

#26
mf

11/19/02

**REQUEST FOR
CONTINUED EXAMINATION (RCE)
TRANSMITTAL**

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000
provides for continued examination of a utility or plant application
filed on or after June 8, 1995.

See The American Inventors Protection Act of 1999 (AIPA)

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

Note: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53(d) instead of a RCE to be eligible for patent term adjustment provisions of the AIPA. See "Changes to Application Examination and Provisional Application Practice," Interim Rule, 65 Fed. Reg. 14865 (March 20, 2000). Off. Gaz. Pat. Office 47 (April 11, 2000), which established RCE practice.

1. Submission required under 37 C.F.R. § 1.114:**a. ☐ Previously submitted**

- i. ☐ Consider the amendment(s)/reply after final under 37 C.F.R. § 1.116 previously filed on _____.
- ii. ☐ Consider the arguments in the Appeal Brief of Reply Brief previously filed on _____.
- iii. ☐ Other _____

b. ☒ Enclosed:

- i. ☒ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement
- iv. ☐ Other _____

RECEIVED
NOV 15 2002
TECH CENTER 1600/2900**2. Miscellaneous**

- a. ☐ Suspension of action on the above-mentioned application is requested under 37 C.F.R. § 1.103(c) for a period of [number] months. (Period of suspension shall not exceed 3 months; fee under 37 C.F.R. § 1.17(i) required.)
- b. ☐ Other _____

11/14/2002 BABRAHA1 00000009 09083150

3. Fees

01 FC:1801

740.00 OP

a. ☒ The filing fee is calculated as follows:

- i. ☒ \$740.00 RCE fee required under 37 C.F.R. § 1.17(e)
- ii. ☐ Petition for extension of time for ([number] Months) \$[Fee]
- iii. ☐ Other _____

b. ☒ Check in the amount of \$740.00 enclosed.

- c. ☒ The Commissioner is authorized to charge any deficiencies in the filing fees, or credit any overpayments to Deposit Account No. 06-0916.

Signature of Applicant, Attorney, or Agent Required

Name: Bryant L. Young

Reg. No.: 49,073

Signature: *Bryant L. Young*

Date: November 12, 2002

Certificate of Mailing or Transmission


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, BOX RCE, Washington, D.C. 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on: [Date]

Name: [Text]

Signature:

Date:

#440851



22852

PATENT TRADEMARK OFFICE

#20/B
11/19/02
PATENT

Customer No. 22,852

Attorney Docket No. 5725-0306-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Boudiaf BOUSSOUIRA et al.

Application No.: 09/083,150

CPA Filed: March 29, 2001

For: COSMETIC USE OF SELECTED
POLYAMINO POLYMERS AS
ANTIOXIDANTS

)
)
) Group Art Unit: 1617
)
) Examiner: E. Webman
)
)
)
)
)

Commissioner for Patents
Washington, DC 20231

Sir:

RECEIVED
NOV 15 2002
TECH CENTER 1600/2900

AMENDMENT AND RESPONSE UNDER 37 C.F.R. § 1.114

This paper fulfills the requirement for a "submission" accompanying a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114. Further to the Notice of Appeal filed September 10, 2002, extending the period for reply until November 12, 2002 (November 10th is a Sunday and November 11th is a Federal Holiday), Applicants respectfully request that the Examiner consider the following amendments and remarks. Please amend the application as follows:

IN THE CLAIMS:

Please substitute claims 1 and 37 for amended claims 1 and 37 as follows:

1. (Amended) A cosmetic and/or dermatological composition comprising in a cosmetically and/or dermatologically acceptable support:
 - at least one nanopigment in said composition,